Mustang Bio, Inc.
corporate_fare Company Profile
Mustang Bio, Inc. (NASDAQ:MBIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 7 items for MBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 7 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for MBIO spans PRE 14A, 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Mustang Bio Seeks 1-for-5 to 1-for-30 Reverse Split to Hold Nasdaq Listing
- Mustang Bio Q3 2026: $14.3M Cash, Wider Loss, New Nasdaq MVLS Delisting Risk
- Mustang Bio Gets Second Nasdaq Grace Period to April 12, 2027; Reverse Split on the Table
- Mustang Bio Receives Nasdaq Delisting Notice; Reports Widened Quarterly Net Loss
- Mustang Bio Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price, Faces October Deadline
Financial Snapshot
Short Interest & Short Volume
2.76 days to coverFINRA reported short interest of 70,238 shares in MBIO as of the October 30, 2026 settlement, a 19.3% increase from the prior period — about 2.8 days to cover at its recent average daily volume. On November 20, 2026, 32.7% of MBIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.